20/20 Biolabs, Inc. Common Stock (AIDX) scores 17 out of 100 on boothcheck's 11-model valuation framework. Verdict: Strong Avoid The estimated fair value is $1.52, representing a 24% premium to fair value. Quantitative score: 35/100. Qualitative score: 20/100.
Analysis includes bear, base, and bull fair value targets using DCF, Graham, regression, and 8 other valuation models.